Literature DB >> 25459360

Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer.

Hung-Jui Tan1, Christopher P Filson2, Mark S Litwin2.   

Abstract

PURPOSE: Although kidney cancer incidence and nephrectomy rates have risen in tandem, clinical advances have generated new uncertainty regarding the optimal management of patients with small renal tumors, especially the elderly. To clarify existing practice patterns, we assessed contemporary trends in the incidence and management of patients with early-stage kidney cancer.
MATERIALS AND METHODS: Using Surveillance, Epidemiology, and End Results data, we identified adult patients diagnosed with T1aN0M0 kidney cancer from 2000 to 2010. We determined age-adjusted and age-specific incidence and management rates (i.e., nonoperative, ablation, partial nephrectomy [PN], and radical nephrectomy) per 100,000 adults and determined the average annual percent change (AAPC). Finally, we compared management groups using multinomial logistic regression accounting for patient characteristics, cancer information, and county-level measures for health.
RESULTS: From 2000 to 2010, we identified 41,645 adults diagnosed with T1aN0M0 kidney cancer. Overall incidence increased from 3.7 to 7.0 per 100,000 adults (AAPC = 7.0%, P<0.001). Over the study interval, rates of PN (AAPC = 13.1%, P<0.001) increased substantially, becoming the most used treatment by 2010. Among the elderly, rates of nonoperative management and ablation approached nephrectomy rates for those aged 75 to 84 years and became the predominant strategy for patients older than 84 years. Adjusting for clinical, oncological, and environmental factors, older patients less frequently underwent PN and more often received ablative or nonoperative management (P<0.001).
CONCLUSIONS: As the incidence of early-stage kidney cancer rises, patients are increasingly treated with nonoperative and nephron-sparing strategies, especially among the most elderly. The broader array of treatment options suggests opportunities to better personalize kidney cancer care for seniors. Published by Elsevier Inc.

Entities:  

Keywords:  Aged; Epidemiology; Kidney neoplasm; Nephrectomy

Mesh:

Year:  2014        PMID: 25459360     DOI: 10.1016/j.urolonc.2014.10.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  8 in total

1.  Trend of Surgical Treatment of Localized Renal Cell Carcinoma.

Authors:  Ramzi B Jabaji; Heidi Fischer; Tyler Kern; Gary W Chien
Journal:  Perm J       Date:  2019

Review 2.  Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon.

Authors:  Robert M Turner; Todd M Morgan; Bruce L Jacobs
Journal:  Urol Clin North Am       Date:  2017-03-14       Impact factor: 2.241

Review 3.  [Renal cell carcinoma in older and geriatric patients].

Authors:  N Wagener
Journal:  Urologe A       Date:  2017-08       Impact factor: 0.639

4.  Antitumor effects of galectin-3 inhibition in human renal carcinoma cells.

Authors:  Yangyang Xu; Changfu Li; Jiahang Sun; Jingshu Li; Xin Gu; Wanhai Xu
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-03

5.  Patient function, long-term survival, and use of surgery in patients with kidney cancer.

Authors:  Hung-Jui Tan; Karim Chamie; Timothy J Daskivich; Mark S Litwin; Jim C Hu
Journal:  Cancer       Date:  2016-08-12       Impact factor: 6.860

6.  Expression of serum microRNA-378 and its clinical significance in renal cell carcinoma.

Authors:  Lixin Shi; Lei Zhang; Chunyang Wang; Shengkun Sun; Xiyuan Cao; Xu Zhang
Journal:  Genet Mol Biol       Date:  2017 Apr-Jun       Impact factor: 1.771

7.  Effect of 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial Nephrectomy on Surgical Outcomes: A Randomized Clinical Trial.

Authors:  Joseph D Shirk; David D Thiel; Eric M Wallen; Jennifer M Linehan; Wesley M White; Ketan K Badani; James R Porter
Journal:  JAMA Netw Open       Date:  2019-09-04

8.  A 14 immune-related gene signature predicts clinical outcomes of kidney renal clear cell carcinoma.

Authors:  Yong Zou; Chuan Hu
Journal:  PeerJ       Date:  2020-10-29       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.